01 · Monitor
Active surveillance
For many low-risk cancers, careful monitoring can avoid or delay treatment while retaining a curative option if the disease changes.
Precision treatment, personal decision
What is the best prostate cancer therapy?
There is no single best treatment for every man. The right choice depends on where the cancer is, how aggressive it is, whether it has spread, your general health and what matters most to you. For carefully selected localised disease, focal ablation may offer a tissue-sparing option worth discussing.
Localised disease
MRI-led planning
Structured follow-up
Treat the focus.
Aim to preserve surrounding prostate tissue whenever clinically appropriate.
The headline says “best”. Medicine says “best for whom?”
Diagnosis first · treatment second · follow-up always
Start with the decision
A treatment plan, not a league table
Prostate cancer ranges from slow-growing disease that may only need active surveillance to aggressive or advanced disease requiring surgery, radiotherapy, systemic treatment, or a combination.
A useful consultation should compare cancer control, urinary and sexual function, recovery, the quality of long-term evidence, and the possibility of further treatment. Focal ablation belongs in that conversation only when the diagnostic picture supports it.
02 · Target
Focal ablation
For selected localised cancers, energy is directed at the known tumour area while aiming to spare untreated tissue.
03 · Treat broadly
Whole-gland treatment
Surgery or radiotherapy may provide the most appropriate established treatment when the cancer pattern or risk requires it.
Focal therapy explained
What is focal ablation?
Focal ablation treats a defined cancer-containing area rather than the whole prostate. Depending on the clinical programme, energy may be delivered using methods such as high-intensity focused ultrasound, cryotherapy, or other ablative technologies.
The intent is to achieve local cancer control while reducing unnecessary damage to nearby structures. That may support better functional outcomes, but it does not eliminate the risks of side effects, residual cancer, recurrence, or further treatment.
The core principle
Treat the clinically significant focus while preserving as much healthy tissue as possible.
Planning: MRI plus targeted and systematic biopsy information
Treatment: ablation of the selected prostate region
Aftercare: scheduled PSA, imaging and biopsy-led follow-up
Patient selection
Who may be considered?
Suitability cannot be decided from PSA alone. It requires review by an experienced team and a clear understanding of the cancer’s grade, volume, location and extent.
Features the team may assess
✓Cancer appears confined to the prostate
✓A clinically significant focus can be accurately defined
✓Tumour position and size are technically treatable
✓The patient understands the evidence and alternatives
✓Long-term follow-up and possible repeat treatment are acceptable
Reasons another approach may be better
×Cancer is not reliably localised or is present in several significant areas
×There is evidence that disease extends beyond the prostate
×The risk profile favours established whole-gland or multimodal treatment
×Accurate post-treatment surveillance would not be possible
×Anatomy or previous treatment creates technical limitations
Important: these are discussion points, not eligibility criteria. Only a specialist review of your full diagnostic record can determine whether focal ablation is reasonable.
Request a specialist review →A careful pathway
From diagnosis to follow-up
01
Confirm the diagnosis
Review PSA history, MRI, biopsy grade and distribution, clinical stage and relevant health factors.
02
Map the cancer
Determine whether the clinically significant disease can be defined precisely enough for targeted treatment.
03
Compare every valid option
Balance expected cancer control, side effects, evidence, recovery, surveillance and personal priorities.
04
Treat the selected area
If focal ablation is chosen, the planned zone is treated with image-guided precision.
05
Stay under active surveillance
Focal treatment is not the end of monitoring. PSA, MRI and repeat biopsy may all form part of follow-up.
An honest comparison
Potential advantages. Real limitations.
Good medical information should explain both sides before asking you to book anything. A surprisingly radical idea, apparently.
+
Why focal ablation is considered
- Targets a defined cancer-containing region
- Aims to preserve untreated prostate tissue
- May reduce some urinary and sexual side effects compared with whole-gland treatment
- May offer a shorter recovery for selected patients
- Can leave established salvage options available if further treatment is needed
!
What must not be overlooked
- Long-term comparative cancer-control evidence is less mature
- Cancer may remain within or outside the treated area
- Repeat ablation or radical treatment may be required
- Urinary, sexual and other complications are still possible
- Follow-up requires more than occasional PSA testing
Current European guidance limits focal ablative therapy to carefully governed clinical trial or registry settings, reflecting the need for stronger long-term comparative evidence. Individual recommendations may differ by clinical context and local practice.
Common questions
Before you decide
Bring these questions — and your actual reports — to a specialist consultation.
Is focal ablation the best prostate cancer therapy?
It may be a reasonable option for some carefully selected patients with localised disease, but it is not the best or safest choice for everyone. Active surveillance, surgery, radiotherapy or systemic treatment may be more appropriate depending on the cancer and the person.
How is suitability for focal ablation assessed?Specialists typically assess PSA history, prostate MRI, targeted and systematic biopsy findings, grade group, cancer volume and location, clinical stage, anatomy, previous treatment, general health and personal priorities.
Does focal ablation guarantee fewer side effects?No. Tissue-sparing treatment may reduce some adverse effects compared with whole-gland treatment, but urinary symptoms, infection, erectile dysfunction, urinary leakage and other complications can still occur. Outcomes vary by patient and technique.
Can prostate cancer return after focal treatment?Yes. Clinically significant cancer may remain or later appear inside or outside the treated area. That is why a structured follow-up programme and willingness to undergo further tests or treatment are essential.
What follow-up is needed?Follow-up is individualised and may include regular PSA tests, clinical review, multiparametric MRI and planned or triggered repeat biopsy. PSA alone cannot always show what is happening in untreated prostate tissue.
What should I bring to a consultation?Bring your PSA timeline, MRI report and images if available, biopsy pathology, staging results, medication list, previous urology records and a short note about the outcomes and side effects that matter most to you.
The next useful step
Find the best option for your diagnosis.
Ask for a specialist assessment that compares focal ablation with every clinically appropriate alternative — clearly, calmly and without pretending that one treatment fits everyone.